UBS Global Biopharma Conference 2026
Logotype for Scholar Rock Holding Corp

Scholar Rock (SRRK) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Scholar Rock Holding Corp

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

U.S. launch and demand

  • Eight weeks after mid-September 2026 U.S. approval, demand was described as solid, broad and steady week to week, spanning adults and children, varied disease trajectories and existing SMN therapies.

  • FDA label covers patients age 2+ receiving an SMN2-targeted therapy; estimated U.S. eligible population ~6,600.

  • 98% of enrolled patients joined Scholar Rock Supports; treatment-naive enrollments exceeded patients previously treated through EAP or ONYX studies.

  • More than one-third of the top 140 U.S. SMA centers had submitted enrollment forms by end-October; demand also reached centers outside the top 140.

  • Muscle strength ranked as the top need in the 2026 Cure SMA survey; three-quarters of neurologists recognized the rationale for targeting both motor neurons and muscle.

Reimbursement and clinical evidence

  • Initial prescription-to-infusion timing was typically 60–90 days or more at launch, with management expecting the interval to shorten as launch processes mature; annual re-verification may still apply.

  • Anthem and Centene published medical policies aligned with the label, representing 47 million covered lives; some patients had already started infusions.

  • A J-code was planned for April 1; coverage policies and the code were expected to support more consistent reimbursement and access.

  • In SAPPHIRE, add-on apitegromab showed a 2.2-point Hammersmith motor-function improvement and nearly 4x greater likelihood of a 3-point-or-more improvement versus placebo.

International expansion

  • EMA application was resubmitted and validated with an alternate fill-finish facility; CHMP opinion expected in H1 2027, followed by a German launch in H2 2027.

  • Japan’s JNDA was accepted for priority review; a ~9-month review plus 60–90 days of pricing discussions could enable launch in late 2027.

  • Global plans include Europe, Japan and up to 50 countries; a German team was ready and Tokyo operations had been established.

  • Management viewed MFN as a minimal concern, citing the rare-disease profile and plans for a narrow global price; the SMA drug category generated well over $5B in annual revenues, with 64% outside the U.S.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Scholar Rock